Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.

ABSTRACT: Oncolytic virus therapy leads to immunogenic death of virus-infected tumor cells and this has been shown in preclinical models to enhance the cytotoxic T-lymphocyte response against tumor-associated antigens (TAAs), leading to killing of uninfected tumor cells. To investigate whether oncolytic virotherapy can increase immune responses to tumor antigens in human subjects, we studied T-cell responses against a panel of known myeloma TAAs using PBMC samples obtained from ten myeloma patients before and after systemic administration of an oncolytic measles virus encoding sodium iodide symporter (MV-NIS). Despite their prior exposures to multiple immunosuppressive antimyeloma treatment regimens, T-cell responses to some of the TAAs were detectable even before measles virotherapy. Measurable bas

SUBMITTER: Packiriswamy N 

PROVIDER: S-EPMC7581629 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature